Understanding, recognizing, and managing toxicities of targeted anticancer therapies

Grace K. Dy, Alex A. Adjei

Research output: Contribution to journalArticle

168 Scopus citations

Abstract

Answer questions and earn CME/CNE Advances in genomics and molecular biology have identified aberrant proteins in cancer cells that are attractive targets for cancer therapy. Because these proteins are overexpressed or dysregulated in cancer cells compared with normal cells, it was assumed that their inhibitors will be narrowly targeted and relatively nontoxic. However, this hope has not been achieved. Current targeted agents exhibit the same frequency and severity of toxicities as traditional cytotoxic agents, with the main difference being the nature of the toxic effects. Thus, the classical chemotherapy toxicities of alopecia, myelosuppression, mucositis, nausea, and vomiting have been generally replaced by vascular, dermatologic, endocrine, coagulation, immunologic, ocular, and pulmonary toxicities. These toxicities need to be recognized, prevented, and optimally managed.

Original languageEnglish (US)
Pages (from-to)249-279
Number of pages31
JournalCA Cancer Journal for Clinicians
Volume63
Issue number4
DOIs
StatePublished - Jan 1 2013

    Fingerprint

Keywords

  • immunotherapeutic agents
  • kinase inhibitors
  • mechanism-based toxicity
  • off-target toxicity
  • targeted agents
  • therapeutic index
  • toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this